$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000115903615000064 Filed on May 11, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$42.50M	$11.97M
YoY Change	255.16%	1.12%
Cost Of Revenue	$6.494M	$5.520M
YoY Change	17.64%	646.96%
Gross Profit	$5.178M	$3.048M
YoY Change	69.88%	296.36%
Gross Profit Margin	12.18%	25.47%
Selling, General & Admin	$9.399M	$10.25M
YoY Change	-8.3%	35.65%
% of Gross Profit	181.52%	336.29%
Research & Development	$16.68M	$21.42M
YoY Change	-22.09%	-2.81%
% of Gross Profit	322.21%	702.59%
Depreciation & Amortization	$421.0K	$397.0K
YoY Change	6.05%	34.58%
% of Gross Profit	8.13%	13.02%
Operating Expenses	$26.08M	$31.67M
YoY Change	-17.63%	7.01%
Operating Profit	-$13.91M	-$25.22M
YoY Change	-44.84%	36.36%
Interest Expense	$1.299M	$1.376M
YoY Change	-5.6%	62.26%
% of Operating Profit
Other Income/Expense, Net	$102.0K	$47.00K
YoY Change	117.02%	-14.55%
Pretax Income	-$15.10M	-$26.50M
YoY Change	-43.02%	37.31%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$19.82M	-$26.55M
YoY Change	-25.36%	37.63%
Net Earnings / Revenue	-46.63%	-221.86%
Basic Earnings Per Share	-$0.12
Diluted Earnings Per Share	-$0.12	-$222.9K
COMMON SHARES
Basic Shares Outstanding	125.3M shares	124.0M shares
Diluted Shares Outstanding	125.3M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$128.5M	$164.5M
YoY Change	-21.88%	88.16%
Cash & Equivalents	$44.29M	$76.57M
Short-Term Investments	$84.20M	$87.90M
Other Short-Term Assets	$9.600M	$8.700M
YoY Change	10.34%	-17.92%
Inventory	$7.482M	$6.765M
Prepaid Expenses
Receivables	$7.725M	$10.96M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$153.3M	$190.9M
YoY Change	-19.69%	71.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.732M	$3.628M
YoY Change	-24.7%	-8.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.100M	$3.100M
YoY Change	0.0%	72.22%
Total Long-Term Assets	$5.796M	$6.773M
YoY Change	-14.42%	17.67%
TOTAL ASSETS
Total Short-Term Assets	$153.3M	$190.9M
Total Long-Term Assets	$5.796M	$6.773M
Total Assets	$159.1M	$197.7M
YoY Change	-19.51%	69.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.299M	$8.658M
YoY Change	-61.9%	200.13%
Accrued Expenses	$12.81M	$12.27M
YoY Change	4.41%	33.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.730M	$2.404M
YoY Change	55.16%	76.5%
Total Short-Term Liabilities	$26.21M	$36.36M
YoY Change	-27.92%	84.1%
LONG-TERM LIABILITIES
Long-Term Debt	$46.00M	$47.40M
YoY Change	-2.95%	59.06%
Other Long-Term Liabilities	$3.127M	$2.343M
YoY Change	33.46%	436.34%
Total Long-Term Liabilities	$3.127M	$2.343M
YoY Change	33.46%	436.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.21M	$36.36M
Total Long-Term Liabilities	$3.127M	$2.343M
Total Liabilities	$29.34M	$38.70M
YoY Change	-24.2%	91.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$465.5M	-$408.6M
YoY Change	13.93%	28.55%
Common Stock	$503.1M	$475.4M
YoY Change	5.83%	35.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.55M	$66.75M
YoY Change
Total Liabilities & Shareholders Equity	$159.1M	$197.7M
YoY Change	-19.51%	69.16%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$19.82M	-$26.55M
YoY Change	-25.36%	37.63%
Depreciation, Depletion And Amortization	$421.0K	$397.0K
YoY Change	6.05%	34.58%
Cash From Operating Activities	-$13.84M	-$17.63M
YoY Change	-21.5%	64.0%
INVESTING ACTIVITIES
Capital Expenditures	$130.0K	$411.0K
YoY Change	-68.37%	-23.03%
Acquisitions
YoY Change
Other Investing Activities	-$10.30M	-$42.80M
YoY Change	-75.93%	-12.47%
Cash From Investing Activities	-$10.42M	-$43.19M
YoY Change	-75.87%	-12.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$107.7M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.157M	$110.0M
YoY Change	-93.5%	-43764.29%
NET CHANGE
Cash From Operating Activities	-$13.84M	-$17.63M
Cash From Investing Activities	-$10.42M	-$43.19M
Cash From Financing Activities	$7.157M	$110.0M
Net Change In Cash	-$17.10M	$49.21M
YoY Change	-134.75%	-181.37%
FREE CASH FLOW
Cash From Operating Activities	-$13.84M	-$17.63M
Capital Expenditures	$130.0K	$411.0K
Free Cash Flow	-$13.97M	-$18.04M
YoY Change	-22.57%	59.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	127260270	shares
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC
CY2014Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	1266000	USD
CY2015Q1	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	66000	USD
CY2014Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2133000	USD
CY2015Q1	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2457000	USD
CY2014Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	6361000	USD
CY2015Q1	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	6074000	USD
CY2014Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	4383000	USD
CY2015Q1	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	4936000	USD
CY2014Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	480000	USD
CY2015Q1	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	522000	USD
CY2014Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	2112000	USD
CY2015Q1	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	1810000	USD
CY2015Q1	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	55000000	USD
CY2015Q1	halo	Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets	12000000	USD
CY2014Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	611000	USD
CY2015Q1	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	872000	USD
CY2014Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	6339000	USD
CY2015Q1	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	6788000	USD
CY2014Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	2380000	USD
CY2015Q1	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3473000	USD
CY2014Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1153846	shares
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3003000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3299000	USD
CY2014Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9760000	USD
CY2015Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	8597000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9149000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7725000	USD
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1035000	USD
CY2015Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-325000	USD
CY2014Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14441000	USD
CY2015Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13335000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13961000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12813000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9219000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9597000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-41000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	491694000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	502980000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3295000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4130000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	746000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	172000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9600000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9400000	shares
CY2014Q4	us-gaap	Assets Assets	165977000	USD
CY2015Q1	us-gaap	Assets Assets	159125000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	161321000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	153329000	USD
CY2014Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	116919000	USD
CY2015Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	120179000	USD
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	74234000	USD
CY2015Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	84212000	USD
CY2015Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	7100000	USD
CY2015Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	77100000	USD
CY2015Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	16
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27357000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76570000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61389000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44287000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	49213000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17102000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125721000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	127163000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125721000	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	127163000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	126000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	127000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26590000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15094000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5520000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6494000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	37185000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	32577000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	54634000	USD
CY2015Q1	us-gaap	Deferred Revenue DeferredRevenue	52626000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7367000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6367000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	47267000	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	46259000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	397000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	421000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5923000	USD
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3079000	USD
CY2014Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2015Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2015Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3419000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1209000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1859000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1424000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4729000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2007000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	595000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1076000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	73000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-68000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	252000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	843000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	1376000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1299000	USD
CY2014Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1400000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1300000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	646000	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1255000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	6406000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	7482000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	553000	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	552000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5207000	USD
CY2015Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	5675000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165977000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	159125000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24331000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26209000	USD
CY2014Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2599000	USD
CY2015Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2031000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	49860000	USD
CY2015Q1	us-gaap	Long Term Debt LongTermDebt	45985000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2015Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	3730000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	110034000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7157000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43191000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10420000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17630000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13839000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-26548000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-15108000	USD
CY2015Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25219000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13911000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2023000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3510000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2000000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2300000	USD
CY2014Q4	us-gaap	Other Assets OtherAssets	1535000	USD
CY2015Q1	us-gaap	Other Assets OtherAssets	1005000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-42000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	14000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3167000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3127000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	47000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	102000	USD
CY2014Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1094000	USD
CY2015Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	921000	USD
CY2014Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	65005000	USD
CY2015Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	33185000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	411000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	130000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11348000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	12187000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10143000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9623000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1205000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2564000	USD
CY2015Q1	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2321000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7157000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	22225000	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	22895000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12170000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12329000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2951000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2732000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21415000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16684000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2015Q1	us-gaap	Restructuring And Related Cost Description RestructuringAndRelatedCostDescription	paid in full
CY2014Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.13
CY2014Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	500000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-450427000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-465535000	USD
CY2014Q1	us-gaap	Revenues Revenues	11966000	USD
CY2015Q1	us-gaap	Revenues Revenues	18666000	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	799000	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	6775000	USD
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.00
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	8568000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9860000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10250000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9399000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3295000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4130000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7200000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8100000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8846153	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	41352000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	37545000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118943000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	125299000	shares
CY2015Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is seeking to translate our unique knowledge of the tumor microenvironment to create novel therapies that have the potential to improve cancer patient survival. Our research focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (“HA”), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as Enhanze</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™</sup></font><font style="font-family:inherit;font-size:10pt;"> technology. rHuPH20 is also the active ingredient in our first commercially approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. When HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 works by temporarily degrading HA surrounding some cancer cells and results in reduced pressure and increased blood flow to the cancer with increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 clinical testing for PEGPH20 in metastatic pancreatic cancer (Study 109-202), and we have recently initiated a clinical trial in non-small cell lung cancer (Study 107-201). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regarding Enhanze, we currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxter Healthcare Corporation (“Baxter”), Pfizer Inc. (“Pfizer”) and Janssen Biotech, Inc. (“Janssen”), with one product approved in the U.S. and three products approved for marketing in Europe from which we are receiving royalties and several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.'s wholly owned subsidiary, Halozyme Holdings Ltd.</font></div></div>

Files In Submission

Name	View Source	Status
0001159036-15-000064-index-headers.html	Edgar Link	pending
0001159036-15-000064-index.html	Edgar Link	pending
0001159036-15-000064.txt	Edgar Link	pending
0001159036-15-000064-xbrl.zip	Edgar Link	pending
ex311q12015.htm	Edgar Link	pending
ex312q12015.htm	Edgar Link	pending
ex32q12015.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
halo-20150331.xml	Edgar Link	completed
halo-20150331.xsd	Edgar Link	pending
halo-20150331_cal.xml	Edgar Link	unprocessable
halo-20150331_def.xml	Edgar Link	unprocessable
halo-20150331_lab.xml	Edgar Link	unprocessable
halo-20150331_pre.xml	Edgar Link	unprocessable
halo1q2015-10q.htm	Edgar Link	pending
pipelineslide19march2015.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2015 Q1 Form 10-Q Financial Statement

#000115903615000064 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2015 Q1 Form 10-Q Financial Statement

#000115903615000064 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo